Justin P. Kline to Animals
This is a "connection" page, showing publications Justin P. Kline has written about Animals.
Connection Strength
0.382
-
The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 02 20; 135(8):523-533.
Score: 0.044
-
Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends Immunol. 2017 07; 38(7):513-525.
Score: 0.037
-
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep. 2016 06 14; 15(11):2357-66.
Score: 0.034
-
PD-1 regulates extrathymic regulatory T-cell differentiation. Eur J Immunol. 2014 Sep; 44(9):2603-16.
Score: 0.030
-
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013 May; 123(5):1999-2010.
Score: 0.028
-
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012 Mar 15; 188(6):2630-42.
Score: 0.025
-
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92.
Score: 0.023
-
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Score: 0.023
-
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52.
Score: 0.021
-
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15; 14(10):3156-67.
Score: 0.020
-
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 2008 Mar; 41(6):505-13.
Score: 0.019
-
Nelarabine in the treatment of refractory T-cell malignant diseases. Expert Opin Pharmacother. 2006 Sep; 7(13):1791-9.
Score: 0.017
-
Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells. Immunity. 2016 Apr 19; 44(4):847-59.
Score: 0.008
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.008
-
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015 Oct; 21(10):1209-15.
Score: 0.008
-
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
Score: 0.008
-
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014 Jan 02; 123(1):15-25.
Score: 0.007
-
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16.
Score: 0.006
-
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44.
Score: 0.005
-
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45.
Score: 0.004
-
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006 Oct 01; 177(7):4521-9.
Score: 0.004